Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially throug

A technology of amphiphilic substances and aggregates, applied in the field of surface aggregates, can solve the problems of low penetration rate and lipid vesicles that are not beneficial

Inactive Publication Date: 2005-11-30
IDEA AG
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the results of the study showed that the application of lipid vesicles is not beneficial (Calpena et al., 1999)
[0026] A study of the skin permeability data for ibuprofen showed that in practice the drug penetration rate was equivalent in solution or in mixed micelles (containing soybean phosphatidylcholine), but in the corresponding lipid dispersion The penetration rate in is almost three times lower (Stoye et al., 1998 (Eur J Pharm Biopharm 46:191-200)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially throug
  • Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially throug
  • Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially throug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-120

[0291] Components:

[0292] 37.74-84.5mg soybean phosphatidylcholine (SPC, -85% purity, MFC)

[0293] Imported as ethanol solution

[0294] SPC / EtOH=1 / 1 V / V and includes about 10%

[0295] Charged phospholipids (presumably anionic phosphatidylglycerol)

[0296] 187-34.9mg Polysorbate (Tween 80, medicinal etc.)

[0297] Level; MDC 1 )

[0298] 5.6-20rel.mol-% sodium dodecyl sulfate (SDS, p.a.; MDC2)

[0299] Replace phospholipids to a given amount

[0300] ad 1ml isotonic phosphate buffer solution (pH=7.2)

[0301] aims : In order to test the synergy between membrane destabilization and thereby increase the adaptability of aggregates, the activity of two different surfactants combined with phospholipids was used as a component of the basic membrane formation system.

[0302] Suspension formulation In order to prepare a series of phospholipid / surfa...

Embodiment 121-129

[0307] Components:

[0308] 14.2mg polysorbate (Tween 80)

[0309] 85.8mg soy phosphatidylcholine (SPC) is the same as in Example 1-120

[0310] 0-17.5rel.mol-% sodium dodecyl sulfate (SDS), equivalent to SPC and

[0311] Replace the phospholipid to the amount given

[0312] ad 1ml isotonic phosphate buffer solution (pH=7.2)

[0313] aims : As in Examples 1-120, test the synergistic effect of different surfactants on the properties of the unfolded surface aggregates.

[0314] Suspension preparation : The method used to prepare the vesicle suspension is the same as that of Examples 1-120. The only significant difference between the test series is slightly larger than the average diameter and polydispersity of the vesicles used in Examples 121-129.

[0315] Transport ability of aggregate suspension (pore penetration ability and adaptability) In order to define the resistance characteristics of the semipermeable barrier with the suspension flow rate (=trans...

Embodiment 130-131

[0319] Component :

[0320] 52.1mg soybean phosphatidylcholine (SPC), the actual amount = 52.2mg-Na

[0321] Cholesterol mg amount

[0322] 45.2mg polysorbate (Tween 80)

[0323] 5,10,15mol-% sodium cholate=Na cholesterol (relative to suspension SPC)

[0324] ad 1ml isotonic phosphate buffer solution (pH=7.2)

[0325] aims : Same as Example 1-120, but using a different charged surfactant (with cholate instead of SDS)

[0326] Suspension preparation The initial suspension was prepared as in the previous example. However, in order to prepare more uniform vesicles in the test formulation before the actual measurement, the initial suspension was pre-filtered through a filter with 80 nm pores. By dynamic light scattering using ALV 5000correlator and a personal computer, the diameter of the bilayer vesicle was determined to be about 120nm.

[0327] Vesicle transport activity (pore penetration capacity / adaptability) The actual transport test is done with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
radiusaaaaaaaaaa
radiusaaaaaaaaaa
radiusaaaaaaaaaa
Login to View More

Abstract

The application describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug; the third component, alternatively, can take the role of a drug. The application further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The application finally reveals suitable methods and favourable conditions for carrier manufacturing and application. The application also describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium.

Description

Technical field [0001] The present application relates to aggregates (extended surface aggregates (extended surface aggregates, ESA)) with expanded surfaces, which have enhanced deformability and improved barrier penetration capabilities. The ESA can be suspended in A suitable liquid medium contains at least three amphipathic components (amphipat) (amphipatic components) and can improve the transport of the active substance through a semipermeable barrier such as the skin, specifically This aggregate is allowed to penetrate the barrier to apply non-invasive drugs to the body. These three amphiphilic substances include at least one membrane forming compound (MFC) that forms the film of the ESA, and at least two membrane destabilizing (membraned estabilising) compounds (MDC). 1 And MDC 2 ), the film destabilizing compounds differ in their ability to form small aggregates (without spreading surface) when alone or in combination with each other and / or are characterized by relatively h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/107A61K9/00A61K9/127A61K31/192A61K31/195A61K31/196A61K31/405A61K31/5415A61K47/10A61K47/16A61K47/24A61K47/26A61K47/34A61K47/44A61P29/00H04B7/005
CPCA61K31/196A61K9/0014A61K9/127A61K31/405A61K31/5415A61K9/1272A61K31/192A61P25/00A61P25/20A61P25/22A61P29/00A61P9/12A61K31/195
Inventor 格雷戈尔·塞维克乌尔里克·维尔
Owner IDEA AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products